-+ 0.00%
-+ 0.00%
-+ 0.00%

Raymond James Initiates Coverage On Aktis Oncology with Strong Buy Rating, Announces Price Target of $40

Benzinga·06/16/2026 09:55:38
Listen to the news
Raymond James analyst Christopher Raymond initiates coverage on Aktis Oncology (NASDAQ:AKTS) with a Strong Buy rating and announces Price Target of $40.